CLA Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Akari Therapeutics, Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.11 |
| 52 Week High | US$3.90 |
| 52 Week Low | US$0.94 |
| Beta | 0.95 |
| 11 Month Change | -45.05% |
| 3 Month Change | -66.96% |
| 1 Year Change | -58.58% |
| 33 Year Change | -96.12% |
| 5 Year Change | -96.85% |
| Change since IPO | -99.66% |
Recent News & Updates
Recent updates
Shareholder Returns
| CLA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -40.0% | -0.7% | -0.02% |
| 1Y | -58.6% | -17.2% | 8.2% |
Return vs Industry: CLA underperformed the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: CLA underperformed the German Market which returned 8.2% over the past year.
Price Volatility
| CLA volatility | |
|---|---|
| CLA Average Weekly Movement | 15.1% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: CLA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: CLA's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 7 | Samir Patel | www.akaritx.com |
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA.
Akari Therapeutics, Plc Fundamentals Summary
| CLA fundamental statistics | |
|---|---|
| Market cap | €14.92m |
| Earnings (TTM) | -€19.36m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.8x
P/E RatioIs CLA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$20.16m |
| Earnings | -US$20.16m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.69 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -14.9% |
How did CLA perform over the long term?
See historical performance and comparison